[Federal Register Volume 59, Number 232 (Monday, December 5, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-29746]


[[Page Unknown]]

[Federal Register: December 5, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

 

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by contacting Leopold J. 
Luberecki, Jr., J.D., Technology Licensing Specialist, Office of 
Technology Transfer, National Institutes of Health, 6011 Executive 
Boulevard, Suite 325, Rockville, Maryland 20852-3804 (telephone 301/
496-7735 ext. 223; fax 301/402-0220). A signed Confidential Disclosure 
Agreement will be required to receive copies of the patent 
applications. Issued patents may be obtained from the Commissioner of 
Patents, U.S. Patent and Trademark Office, Washington, DC 20231.

Recombinant Vaccinia Virus Encoding Cytochromes P-450

Gelboin, H.V., Battula, N., Gonzalez, F.J., Moss, B. (NCI, NIAID)
Serial No. 07/787,777 filed 6 Nov 91
U.S. Patent 5,164,313 issued 17 Nov 92
Serial No. 08/166,287
Filed 13 Dec 93 [FWC of 07/930,781 (Aban), which is DIV of 07/787,777]

    This invention describes the construction and uses of recombinant 
vaccinia viruses containing DNA sequences that express enzymatically 
active cytochromes P1-450 and P3-450 in mammalian cells without 
requiring the extraneous addition of NADPH cytochrome P450 reductase or 
cell fractions for catalytic activity. This novel recombinant virus can 
be used to evaluate the cytochrome P-450-mediated metabolism and 
mutagenicity of xenobiotic or endobiotic compounds and chemical agents. 
The invention represents the first expression of cytochrome P-450 in a 
variety of mammalian systems using infectious viruses.

Chemotherapeutic Agent Evaluation Using Cells Grown In Hollow Fibers In 
Vivo

Hollingshead, M.G. (NCI)
Filed 5 May 93
Serial No. 08/058,154

    A novel method has been developed to quickly evaluate and screen 
potential anti-cancer and anti-viral drugs in vivo. The desire for 
effective treatments for tumors and viral infections has created a need 
in the research and medical communities for a quick, reliable way to 
test chemotherapeutic agents. Although several teams of investigators 
have attempted in recent years to develop in vivo methods for screening 
such drugs, these methods have had limited value because they usually 
permit only the agent to be tested against one type of tumor cell or 
cell line per experiment and/or have been labor intensive and 
expensive. This new method for screening chemotherapeutic agents 
involves encapsulating the target (i.e., tumor) cells in a 
biocompatible, semipermeable membrane--which is made of unique hollow 
fibers or dialysis tubing--and transplanting the encapsulated cells 
into a laboratory animal. Each laboratory animal can receive an implant 
at a single site or multiple sites, making it possible to test a 
chemotherapeutic agent against several types of tumor cells 
simultaneously. The membrane, which does not generate an autoimmune 
response or release any toxic chemicals, allows for the target cells to 
be reharvested after the treatment.

Sensitive Method For Locating Chromosomal Breakpoints

Magrath, I.T., Shiramizu, B. (NCI)
Filed 2 Dec 93
Serial No. 08/160,547 (CON of 07/698,233, CON of 07/441,516)

    A new technique for localizing chromosomal breakpoints offers a 
significant advancement in detecting genetic translocations such as 
those found in Burkitt's lymphoma. Present techniques for detecting 
chromosomal breakpoints require large amounts of tumor sample, are 
often insensitive, or are cumbersome and time consuming. This new 
technique utilizes sequence-specific primers for rapid, efficient PCR 
amplification of a fragment containing a breakpoint. This technique is 
so sensitive it can be used to sub-divide Burkitt's lymphomas into 
subtypes based on the location of chromosomal breakpoints.

Method For Estimating mRNA Content By Filter Hybridization To A 
Polythymidylate Probe

Hollander, M.C., Fornace, A.J. (NCI)
Filed 21 Feb 94
Serial No. 08/183,911 (CON of 07/908,814, CON of 07/501,774)

    A method for the quantitation of relative mRNA samples which 
entails hybridization of a polythymidylate (polyT) probe with RNA bound 
to an insoluble substrate. This method is especially applicable for 
normalizing numerous RNA samples which are to be analyzed by dot blot 
hybridization. The relative hybridization of polyT probe to RNA is 
proportional to the polyA RNA content of the RNA samples. Since the 
hybridization of polyT probe to RNA does not appear to be dependent on 
any cell treatment or growth condition and experimental variation is 
minimized, this method is a better method for standardizing the amount 
of mRNA in RNA samples than is relative hybridization to cDNA probes 
such as actin or 2-microglobulin, the transcript levels 
of which may vary according to cell treatment.

Sphingoid Bases And Methods For Their Preparation And Use

Boumendjel, A., Miller, S.P.F. (NINDS)
Filed 14 Feb 94
Serial No. 08/195,815

    This is a new method for synthesizing a group of novel analogs of 
sphingosine-1-phosphate (S-1-P) that offer improved methods of studying 
cell growth as well as other cell regulatory processes. Sphingolipids 
compromise a large class of biologically significant compounds, some of 
which act upon enzymes that control cell growth or have potent mitogen 
activity. Previously, it has been difficult to study this class of 
compounds because there was no economically feasible method of 
producing large-scale amounts; however, a method has been developed for 
synthesizing S-1-P and other related analogs with greater yields and 
quantities in a shorter period of time compared to previous methods, 
allowing for large-scale production of these compounds at much lower 
costs.

A Novel Chaperone Protein

Kaye, F.J., Otterson, G.A. (NCI)
Filed 28 Feb 94
Serial No. 08/203,905

    The gene sequences for the rat and human Stch chaperone protein, 
which belongs to the heat shock protein (HSP) family, have been 
isolated and characterized. HSP products have been localized to 
specific cellular fractions, such as cytosol, nucleus, endoplasmic 
reticulum, and mitochondria, and recent experimental models have 
implicated these ``chaperones'' in facilitating protein transport 
across these specialized compartments. The Stch protein has significant 
differences from previously identified heat shock proteins and is 
expressed in tumor origin cells. These novel gene sequences and probes 
derived from the gene sequences are useful for quantitating the amount 
of Stch gene transcript in tissues, and antibodies are useful for 
detecting the presence of protein in cells.

Genes Coding For Melanoma Tumor Antigens

Kawakami, Y., Rosenberg, S.A. (NCI)
Filed 22 Apr 94
Serial No. 08/231,565

    Genes have been isolated that code for melanoma tumor antigens, 
which may provide an important new method for the prevention or 
treatment of this deadly form of cancer. Melanomas are aggressive, 
frequently metastatic tumors, and even when the melanoma is apparently 
localized to the skin, up to 30 percent of patients eventually will 
have the tumor spread to other organs and tissues of the body. The 
majority of these individuals will die. Recent studies have shown that 
many melanoma patients mount cellular and humoral responses against 
these tumors and that melanomas express both MHC antigens and tumor-
associated antigens. These newly discovered melanoma antigen genes may 
be used in gene therapy protocols, or peptides derived from the gene 
product may be used in vaccines to help the recipient mount a T-cell-
mediated immune response against the melanoma.

    Dated: November 16, 1994.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 94-29746 Filed 12-2-94; 8:45 am]
BILLING CODE 4140-01-P